http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rein+Therapeutics%2C+Inc.+++For%3A+Aug+21/26989840.html si-local-file:///var/storage/secattach/20260827/26989840.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rein+Therapeutics%2C+Inc.+++For%3A+Aug+21/26989840.html Thu, 27 Aug 2026 16:05:00 -0400 O.06768047 RNTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rein+Therapeutics%2C+Inc.+++For%3A+Aug+21/26989840.html si-local-file:///var/storage/secattach/20260827/26989840.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Rein+Therapeutics%2C+Inc.+++For%3A+Aug+21/26989840.html Thu, 27 Aug 2026 16:05:00 -0400 O.06768047 RNTX http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Rein+Therapeutics+drug+for+lung+fibrosis/26953200.html <p>Rein Therapeutics (NASDAQ: RNTX) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>Fast Track designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs. Drugs receiving this designation may be eligible for more frequent interactions with the FDA, rolling marketing application submissions, and potential consideration for Accelerated Approval and Priority Review if applicable criteria are met.</p> <p>IPF is a chronic, progressive lung disease in which scar tissue http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Rein+Therapeutics+drug+for+lung+fibrosis/26953200.html Thu, 20 Aug 2026 08:00:50 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Rein+Therapeutics+drug+for+lung+fibrosis/26953200.html <p>Rein Therapeutics (NASDAQ: RNTX) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>Fast Track designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs. Drugs receiving this designation may be eligible for more frequent interactions with the FDA, rolling marketing application submissions, and potential consideration for Accelerated Approval and Priority Review if applicable criteria are met.</p> <p>IPF is a chronic, progressive lung disease in which scar tissue http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Rein+Therapeutics+drug+for+lung+fibrosis/26953200.html Thu, 20 Aug 2026 08:00:50 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Rein+Therapeutics+drug+for+lung+fibrosis/26953200.html <p>Rein Therapeutics (NASDAQ: RNTX) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>Fast Track designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs. Drugs receiving this designation may be eligible for more frequent interactions with the FDA, rolling marketing application submissions, and potential consideration for Accelerated Approval and Priority Review if applicable criteria are met.</p> <p>IPF is a chronic, progressive lung disease in which scar tissue http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Rein+Therapeutics+drug+for+lung+fibrosis/26953200.html Thu, 20 Aug 2026 08:00:50 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Rein+Therapeutics+drug+for+lung+fibrosis/26953200.html <p>Rein Therapeutics (NASDAQ: RNTX) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its drug candidate LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>Fast Track designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs. Drugs receiving this designation may be eligible for more frequent interactions with the FDA, rolling marketing application submissions, and potential consideration for Accelerated Approval and Priority Review if applicable criteria are met.</p> <p>IPF is a chronic, progressive lung disease in which scar tissue http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Rein+Therapeutics+drug+for+lung+fibrosis/26953200.html Thu, 20 Aug 2026 08:00:50 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression</em></li><li style="margin-bottom:8pt;"><em>Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026</em></li></ul> <p><br/>AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression</em></li><li style="margin-bottom:8pt;"><em>Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026</em></li></ul> <p><br/>AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression</em></li><li style="margin-bottom:8pt;"><em>Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026</em></li></ul> <p><br/>AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression</em></li><li style="margin-bottom:8pt;"><em>Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026</em></li></ul> <p><br/>AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression</em></li><li style="margin-bottom:8pt;"><em>Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026</em></li></ul> <p><br/>AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression</em></li><li style="margin-bottom:8pt;"><em>Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026</em></li></ul> <p><br/>AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression</em></li><li style="margin-bottom:8pt;"><em>Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026</em></li></ul> <p><br/>AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html <ul type="disc"><li style="margin-bottom:8pt;"><em>Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progression</em></li><li style="margin-bottom:8pt;"><em>Actively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03 in IPF; on track to report interim data in the second half of 2026</em></li></ul> <p><br/>AUSTIN, Texas, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LTI-03 for the treatment of http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Receives+U.S.+FDA+Fast+Track+Designation+for+LTI-03+in+Idiopathic+Pulmonary+Fibrosis/26953131.html Thu, 20 Aug 2026 08:00:00 -0400 A.06822034 O.06768047 O.20026344 RNTX http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Rein+Therapeutics+%28RNTX%29/26940279.html <p>H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $8.00 price target on Rein Therapeutics (NASDAQ: RNTX).</p><p>The analyst commented: "With RENEW enrollment ahead of schedule and initial Phase 2 data expected in 2H26, we believe RNTX is entering a more catalyst-driven period as investors begin to assess whether LTI-03’s Phase 1b biology can translate into clinical benefit in IPF. The trial has now surpassed 25% enrollment, or more than 30 of the planned ~120 patients, enrollment is tracking ahead of schedule across all five planned countries, and Rein remains on track to report initial/interim data in 2H26. This is http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Rein+Therapeutics+%28RNTX%29/26940279.html Tue, 18 Aug 2026 06:43:26 -0400 RNTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rein+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933327.html si-local-file:///var/storage/secattach/20260814/26933327.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rein+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933327.html Fri, 14 Aug 2026 21:32:00 -0400 O.06768047 RNTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rein+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933327.html si-local-file:///var/storage/secattach/20260814/26933327.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Rein+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+ADAR1+Capital+Management%2C+LLC/26933327.html Fri, 14 Aug 2026 21:32:00 -0400 O.06768047 RNTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rein+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+Lynwood+Capital+Management+Inc./26930451.html si-local-file:///var/storage/secattach/20260814/26930451.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rein+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+Lynwood+Capital+Management+Inc./26930451.html Fri, 14 Aug 2026 16:13:00 -0400 O.06768047 RNTX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rein+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+Lynwood+Capital+Management+Inc./26930451.html si-local-file:///var/storage/secattach/20260814/26930451.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Rein+Therapeutics%2C+Inc.++++++++++++++++Filed+by%3A+Lynwood+Capital+Management+Inc./26930451.html Fri, 14 Aug 2026 16:13:00 -0400 O.06768047 RNTX http://www.streetinsider.com/Earnings/Rein+Therapeutics+Inc.+%28RNTX%29+Tops+Q2+EPS+by+39c/26924587.html <p>Rein Therapeutics Inc. (NASDAQ: RNTX) reported Q2 EPS of ($0.10), $0.39 better than the analyst estimate of ($0.49).</p><p>For earnings history and earnings-related data on Rein Therapeutics Inc. (RNTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=RNTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Rein+Therapeutics+Inc.+%28RNTX%29+Tops+Q2+EPS+by+39c/26924587.html Fri, 14 Aug 2026 07:31:38 -0400 RNTX http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26924289.html <ul type="disc"><li><em>Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026</em></li><li><em>Successfully completed oversubscribed $57.5 million public offering supported by both new and existing healthcare-focused investors</em></li></ul> <p>AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.</p> <p>“We ended the second http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26924289.html Fri, 14 Aug 2026 06:44:00 -0400 O.06768047 RNTX http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26924289.html <ul type="disc"><li><em>Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026</em></li><li><em>Successfully completed oversubscribed $57.5 million public offering supported by both new and existing healthcare-focused investors</em></li></ul> <p>AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.</p> <p>“We ended the second http://www.streetinsider.com/Press+Releases/Rein+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26924289.html Fri, 14 Aug 2026 06:44:00 -0400 O.06768047 RNTX http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26924289.html <ul type="disc"><li><em>Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026</em></li><li><em>Successfully completed oversubscribed $57.5 million public offering supported by both new and existing healthcare-focused investors</em></li></ul> <p>AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.</p> <p>“We ended the second http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26924289.html Fri, 14 Aug 2026 06:44:00 -0400 O.06768047 RNTX http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26924289.html <ul type="disc"><li><em>Surpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026</em></li><li><em>Successfully completed oversubscribed $57.5 million public offering supported by both new and existing healthcare-focused investors</em></li></ul> <p>AUSTIN, Texas, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (&quot;Rein&quot;) (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.</p> <p>“We ended the second http://www.streetinsider.com/Globe+Newswire/Rein+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26924289.html Fri, 14 Aug 2026 06:44:00 -0400 O.06768047 RNTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Rein+Therapeutics%2C+Inc.+++For%3A+Jun+30/26924249.html si-local-file:///var/storage/secattach/20260814/26924249.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Rein+Therapeutics%2C+Inc.+++For%3A+Jun+30/26924249.html Fri, 14 Aug 2026 06:34:00 -0400 O.06768047 RNTX